Genmab stock price target raised to $32 from $24 at TD Cowen on MRUS deal
PositiveFinancial Markets

Genmab's stock price target has been raised from $24 to $32 by TD Cowen, following a significant deal involving MRUS. This adjustment reflects growing confidence in Genmab's potential and the positive impact of the MRUS agreement on its future performance. Investors may see this as a strong indicator of the company's upward trajectory, making it an exciting time for stakeholders.
— Curated by the World Pulse Now AI Editorial System